SOLID ORAL PHARMACEUTICAL COMPOSITION OF S1P AGONIST OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD FOR ITS PRODUCTION AND METHODS FOR TREATMENT AND REDUCTION OF FREQUENCY OF CLINICAL EXACERBATIONS OF MULTIPLE SCLEROSIS Russian patent published in 2017 - IPC A61K31/137 A61K47/36 A61K47/12 A61K9/20 A61K9/48 A61P25/28 

FIELD: pharmacology.

SUBSTANCE: solid oral pharmaceutical composition consists of phignolimide hydrochloride in an amount of 0.4-0.65 mg, pregelatinized starch in an amount of 145-155 mg and magnesium stearate in an amount of 1.0-2.0 mg. The composition can be presented in the form of a pill or a capsule. The composition intended for treatment of relapsing-remitting multiple sclerosis, to reduce the frequency of clinical exacerbations of the disease and reduce the risk of disability progression in relapsing-remitting multiple sclerosis. The composition is administered orally in a dose of 500 μg, once a day.

EFFECT: composition according to the invention is characterized by a high homogeneity of the active substance dosage, stability for prolonged storage and is capable of disintegrating and releasing the active substance rapidly during oral administration.

5 cl, 10 tbl, 8 ex